25 suspended. 25 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Suspended 25 |
| Phase 2 | 6 | Suspended 6 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 53 | 2026-11-18 | 2026-08-24 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia CAR-T cells( chimeric antigen receptor T cells) - Relapsed/Refractory Acute Myeloid Leukemia(AML) | Phase 1 | Suspended | He Huang | 24 | 2025-01-08 | 2025-11-24 |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 45 | 2024-12-18 | 2026-08-25 |
| Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 24 | 2024-11-06 | 2026-11-12 |
| DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial Decoy-resistant interleukin-18, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Suspended | Fred Hutchinson Cancer Center | 40 | 2024-09-23 | 2026-08-10 |
| 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML CRD3874 - Acute Myeloid Leukemia | Phase 1 | Suspended | University of Maryland, Baltimore | 6 | 2024-08-26 | 2026-03-12 |
| Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 33 | 2024-05-24 | 2026-10-15 |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant CD4CAR - Acute Myeloid Leukemia | Phase 1 | Suspended | Huda Salman | 30 | 2024-03-19 | 2026-09-30 |
| Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. CD4CAR - Chronic Myelomonocytic Leukemia | Phase 1 | Suspended | Huda Salman | 30 | 2024-02-21 | 2026-09-24 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia 8-Chloroadenosine, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 30 | 2022-10-31 | 2026-10-20 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) fadraciclib - Leukemia, Myelodysplastic Syndrome(MDS) | Phase 1 / Phase 2 | Suspended | Cyclacel Pharmaceuticals, Inc. | 210 | 2021-10-22 | 2024-02-08 |
| A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia SY-2101, Arsenic Trioxide - Acute Promyelocytic Leukemia | Phase 1 | Suspended | Syros Pharmaceuticals | 16 | 2021-09-17 | 2024-01-23 |
| Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies anti-TRBC1 CAR-T cell therapy - Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Suspended | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 9 | 2021-03-31 | 2023-11-29 |
| Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia IBI188, Azacitidine, Decitabine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Suspended | Innovent Biologics (Suzhou) Co. Ltd. | 222 | 2020-09-25 | 2023-10-23 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Suspended | Curis, Inc. | 366 | 2020-07-06 | 2026-03-19 |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Decitabine, Pembrolizumab, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Suspended | City of Hope Medical Center | 54 | 2020-05-19 | 2026-10-20 |
Showing 20 of 25. Sign in to see all of them.
Leukemia, Myeloid, Acute (15) · Myelodysplastic Syndromes (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Immunoblastic Lymphadenopathy (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Peripheral (2) · Recurrence (2) · Burkitt Lymphoma (1) · Colorectal Neoplasms (1)
Hematologic Diseases (25) · Hemic and Lymphatic Diseases (25) · Neoplasms by Histologic Type (25) · Neoplasms (24) · Leukemia, Myeloid (17) · Bone Marrow Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Leukemia, Lymphoid (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Specimen Handling (6) · venetoclax (6) · Azacitidine (3) · Biopsy (3) · Cyclophosphamide (2) · Decitabine (2) · Magnetic Resonance Spectroscopy (2) · Melphalan (2) · Tacrolimus (2) · fludarabine (2) · fludarabine phosphate (2) · 8-chloroadenosine (1) · Actinium (1) · Antibodies, Monoclonal (1) · Arsenic Trioxide (1)
City of Hope Medical Center (5) · Huda Salman (2) · National Cancer Institute (NCI) (2) · Curis, Inc. (1) · Cyclacel Pharmaceuticals, Inc. (1) · David Wald (1) · Fred Hutchinson Cancer Center (1) · He Huang (1) · Humanigen, Inc. (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · MedImmune LLC (1) · Piramal Enterprises Limited (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shanghai Jiao Tong University School of Medicine (1) · SymBio Pharmaceuticals (1)
United States (20) · China (5) · Australia (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Poland (1) · Singapore (1) · Spain (1)
Alan S. Wayne, MD (1) · Amandeep Salhotra (1) · Annie P Im (1) · Benjamin Tomlinson, MD (1) · Dr Alexey V Danilov, MD, PhD (1) · Dr Jennifer R Brown, MD, PhD (1) · Elizabeth Krakow (1) · Geoffrey Uy, M.D. (1) · Hongtao Liu (1) · Huda Salman, MD, PhD (1) · Ibrahim Aldoss (1) · Jennifer Schwartz, MD (1) · Jiong HU, M.D., (1) · Manu Pandey (1)
P30CA033572 (5), P30CA014599 (1), UM1CA186689 (1), UM1CA186690 (1)